Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas
Rhea-AI Summary
Daxor (Nasdaq: DXR) will exhibit for the first time at the 14th Annual Dysautonomia International Conference, held July 9–12, 2026, at The Woodlands Marriott Waterway Hotel & Convention Center in The Woodlands, Texas.
The company will showcase its FDA-cleared next-generation rapid, lightweight, lab-based Blood Volume Analyzer (BVA™), highlighting how objective plasma and red blood cell volume data may help target dysautonomia therapy and support more data-driven, precision care.
Positive
- None.
Negative
- None.
News Market Reaction – DXR
In the Jul 7 session, DXR declined 0.28%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | patent announcement | Positive | +2.9% | U.S. patent granted for remote blood volume monitoring technology. |
| Apr 28 | conference exhibition | Positive | +5.4% | Planned BVA exhibition at MedAxiom CV Transforum Spring’26 forum. |
| Apr 08 | customer expansion | Positive | +2.3% | Launch of new BVA program at high-volume Ohio cardiology center. |
| Mar 26 | clinical data | Positive | -2.9% | SCCM 2026 data validating BVA’s accuracy for albumin escape rate. |
| Mar 17 | conference exhibition | Positive | +0.2% | ACC.26 exhibition of portable BVA and associated outcome data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Daxor news has typically seen positive price reactions, with only one of the last five headlines drawing a negative next-day move.
Key Terms
dysautonomia medical
autonomic disorders medical
plasma medical
red blood cell medical
peripheral hematocrit medical
intravascular status medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Daxor to Showcase How BVA Provides the Objective Plasma and Red Blood Cell Data Needed to Target Dysautonomia Therapy
Oak Ridge, TN, July 07, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting for the first time at the 14th Annual Dysautonomia International Conference. Daxor will feature its FDA-cleared next-generation rapid, lightweight, lab-based Blood Volume Analyzer (BVA™). The premier global event for autonomic disorders will take place from July 9–12, 2026, at The Woodlands Marriott Waterway Hotel & Convention Center in The Woodlands, Texas.
This year’s conference theme, "Piece by Piece: Building the Future of Dysautonomia Care," brings together the world’s leading physicians, researchers, clinicians, and patient advocates. Daxor’s presence underscores a major paradigm shift in autonomic medicine: shifting away from subjective symptom tracking and moving toward objective, precision data.
“For too long, dysautonomia patients have faced an uphill battle due to the limitations of traditional diagnostics," said John L. Jefferies, MD, MPH, MBA, Daxor's Chief Medical Officer. "Standard assessments like peripheral hematocrit, blood pressure, or heart rate frequently fail to reflect a patient's true intravascular status. BVA replaces clinical guesswork with objective data. By obtaining accurate baselines for both plasma and red blood cell volumes, physicians can deliver a truly targeted, data-driven therapeutic response with clinical precision.”
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.
For more information, please visit our website at Daxor.com.
Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact
Bret Shapiro
COO – Head of Capital Markets
COREIR
516-222-2560
brets@coreir.com|www.coreir.com
